INTRODUCTION
============

An estimated 124-283 million of malaria clinical cases occur annually, and the disease continues to be a serious health threat in developing countries \[[@b1-kjp-53-4-403]\]. Malaria is caused by *Plasmodium* spp., and of them *Plasmodium vivax* is geographically the most widely spread species \[[@b2-kjp-53-4-403]\]. Moreover, control and understanding of vivax malaria have limitation from lack of *P. vivax* continuous culture \[[@b3-kjp-53-4-403]-[@b5-kjp-53-4-403]\]. To overcome this constraint, various new approaches using bioinformatics data were tried and used for development of antimalarial drugs and vaccines \[[@b6-kjp-53-4-403],[@b7-kjp-53-4-403]\].

In the blood stage, *Plasmodium* spp. invade erythrocytes or reticulocytes by use of an actin-myosin motor \[[@b8-kjp-53-4-403],[@b9-kjp-53-4-403]\]. This process internalizes the parasite in red blood cells (RBCs), followed by growth and replication to form the merozoites. The invasive merozoites egress from infected RBCs to invade new host cells \[[@b10-kjp-53-4-403]-[@b12-kjp-53-4-403]\]. In this step, specific receptors on the surface of host RBCs are required for interaction involved with attachment, reorientation, and junction formation for parasite invasion \[[@b12-kjp-53-4-403]\]. During these multiple steps, many proteins mediate the interaction between RBCs and parasites \[[@b13-kjp-53-4-403],[@b14-kjp-53-4-403]\]. One of these proteins is Duffy binding protein of *P. vivax* (PvDBP), which is essential for invasion of vivax parasites into RBCs. The invasion utilizes the Duffy antigen/receptor for chemokines (DARC) on the surface of RBCs \[[@b15-kjp-53-4-403],[@b16-kjp-53-4-403]\]. PvDBP and DARC were only one of the unique and essential ligand-receptors for erythrocyte invasion of *P. vivax* \[[@b17-kjp-53-4-403]\]. Recently, clinical vivax patients were observed in Duffy-negative populations of Madagascar, where mixture of Duffy-positive and Duffy-negative populations has lived together \[[@b18-kjp-53-4-403]\]. Thus, new questions have arisen with regards to the Duffy-independent *P. vivax* invasion of erythrocytes.

Reticulocyte binding-like (RBL) family proteins are possible candidates for alternative invasion pathway after PvDBP-DARC interaction. RBL proteins may interact with reticulocytes by an independent pathway with the Duffy phenotype, suggesting that the RBL family may use a novel receptor for reticulocyte invasion. RBL proteins feature a small and large exon separated by a small intron, and the small exon encodes the signal peptide \[[@b19-kjp-53-4-403],[@b20-kjp-53-4-403]\]. The complete gene sequence of *P. vivax* Salvador I (Sal-1) strain comprises genes for 11 *P. vivax* reticulocyte binding proteins (PvRBP) as well as 2 pseudogenes \[[@b14-kjp-53-4-403],[@b21-kjp-53-4-403]\]. Five of these genes are highly expressed in schizont stage during the erythrocytic stage of *P. vivax* parasites \[[@b22-kjp-53-4-403],[@b23-kjp-53-4-403]\]. However, no studies have addressed the antigenicity of PvRBPs from vivax malaria patients in endemic countries.

In infectious diseases, identification of the antigenic domain(s) is important for diagnosis and vaccine development \[[@b24-kjp-53-4-403],[@b25-kjp-53-4-403]\]. Numerous studies supported the accuracy of the specific domain prediction such as B-cell epitopes in infectious diseases \[[@b24-kjp-53-4-403]-[@b26-kjp-53-4-403]\]. Several B-cell epitope prediction systems based on bioinformatics data including ABCpred, BcePred, and BepiPred have been reported \[[@b27-kjp-53-4-403]-[@b33-kjp-53-4-403]\]. ABCpred predicts B-cell epitopes in an antigen sequence using an artificial recurrent neural network. This program is able to predict epitopes with 65.9% accuracy \[[@b29-kjp-53-4-403],[@b31-kjp-53-4-403]\]. BcePred predicts linear B-cell epitopes on the basis of their physico-chemical properties (hydrophilicity, flexibility, mobility, accessibility, polarity, exposed surface, and turns) and produces epitopes with 58.7% accuracy using flexibility, hydrophilicity, polarity, and exposed surface factor score combined at a recommendation threshold of 2.38 \[[@b28-kjp-53-4-403]\]. The BepiPred sever has been used to predict the location of linear B-cell epitopes using a combination of a hidden Markov model and propensity scale method \[[@b30-kjp-53-4-403],[@b34-kjp-53-4-403]\]. This B-cell epitope prediction might be useful to decide antigenic domains in the *P. vivax* RBL family proteins. This information would be helpful for increased understanding of the PvRBP family as a potential antigenic candidate.

In the present study, PvRBP family protein sequences were analyzed to predict B-cell epitope domains by in-silico data mining. Each recombinant PvRBP including B-cell epitope domains was expressed in a wheat germ cell-free expression system (WGCF). The humoral immune responses against PvRBPs were observed to evaluate the probability of a potential antigenic candidate by protein microarray-based serological screening.

MATERIALS AND METHODS
=====================

Human serum and parasite samples
--------------------------------

Human serum samples were collected from 16 *P. vivax* positive patients from an endemic area of Gangwon-do (Province), Republic of Korea (Korea). Vivax infections were confirmed by microscopic examination and detection of malaria antigen by P.f/Pan rapid diagnosis test kit (SDFK60) (SD Diagnostics, Giheung, Korea). Serum samples were collected from 8 healthy individuals with no history of malaria living in non-endemic areas of Gangwon-do. This study was approved by the Institutional Review Board at Kangwon National University Hospital. The individual serum samples were examined for humoral immune responses by protein array. Genomic DNA was extracted from 200 μl whole blood of the *P. vivax* patients using QIAamp DNA Blood Mini Kits (Qiagen, Hilden, Germany) according to the manufacturer's protocol.

Prediction of linear B-cell epitopes for PvRBP family
-----------------------------------------------------

The in-silico prediction of linear B-cell epitopes was conducted by ABCpred (<http://imtech.res.in/raghava/abcpred/>), BcePred (<http://www.imtech.res.in/raghava/bcepred/>), and BepiPred (<http://www.cbs.dtu.dk/services/BepiPred/>) to heighten the accuracy. For prediction of B-cell epitopes, PvRBP family sequences were obtained from PlasmoDB (<http://plasmodb.org/plasmo/>) ([Table 1](#t1-kjp-53-4-403){ref-type="table"}). Each sequence was allowed in the B-cell epitope prediction with each prediction server. ABCpred setting was up to 20 mer peptides by overlapping filter and a threshold value of 0.51 (ABCpred base threshold value). The predicted B-cell epitopes were ranked according to their score obtained by a trained recurrent neural network. Higher scores (\>0.90) were chosen for B-cell epitope combination analysis for each protein. BcePred predicted linear B-cell epitopes based on physico-chemical properties using values of hydrophilicity (2.0), flexibility (1.9), accessibility (2.0), turns (1.9), exposed surface value (2.4), polarity (2.3), and antigenic propensity (1.8) to calculate a threshold value at 1.9. BepiPred 1.0 was set for each PvRBPs sequence using a threshold value of 1.3, which represented B-cell epitope prediction sensitivity and specificity of 13% and 96%, respectively. Each *PvRBP* family was analyzed for flexibility, antigenic index, and surface location by the Protean protein secondary structure prediction program (Lasergene, Madison, Wisconsin, USA). Finally, 20 PvRBP family fragments were selected from the combination of predicted B-cell epitopes listed from the highest scores for humoral immune response analysis.

Expression of recombinant PvRBPs B-cell epitope fragments
---------------------------------------------------------

PvRBP family sequences from PlasmoDB were used to design primers of gene amplification for B-cell epitope fragments ([Table 2](#t2-kjp-53-4-403){ref-type="table"}). Expected molecular weight and isoelectric point for B-cell epitope fragments are shown in [Table 2](#t2-kjp-53-4-403){ref-type="table"}. For recombinant protein expression vector construction, pEU-E01-His-TEV-MCS vector containing a 6× His tag at the N-terminus (CellFree Science, Matsuyama, Japan) was used. After restriction enzyme digestion of pEU vector with *XhoI* and *Bam*HI, the target amplicon was cloned into the pEU vector by an Infusion cloning system (Clontech, Mountain View, California, USA). The sequences of each protein fragment were analyzed using an ABI 3700 genetic analyzer (Genotech, Daejeon, Korea) and were used for small-scale WGCF expression in the Cell-Free Expression Kit (CellFree Sciences) according to the manufacturer's protocol. Recombinant crude protein (10 μl) was mixed with reducing sample buffer and total and soluble fractions were obtained by centrifugation (12,000 g). For target protein detection, recombinant proteins were separated using 12% SDS-PAGE and detected by Western blot analysis. Briefly, the electrophoretically resolved proteins were transferred to polyvinyl difluoride membranes (Millipore, Bedford, Massachusetts, USA). Specific proteins were detected by mouse anti-penta-His antibody (Qiagen) in a 1:2,000 dilution of 0.2% Tween 20 in phosphate-buffered saline (PBS-T). The primary antibody reaction was detected by a 1:5,000 dilution of goat anti-mouse IRDye CW800 secondary antibody (LI-COR Biosciences, Lincoln, Nebraska, USA) in PBS-T. Western blot results were determined with an Odyssey infrared imaging system and incorporated software (LI-COR Biosciences) at a wavelength of 680 nm.

Analysis of humoral immune responses to recombinant PvRBPs
----------------------------------------------------------

For humoral immune response analysis, the protein array analysis was done as follows. Tri-amine coated slides were prepared by trimethoxysilane (Sigma-Aldrich, St Louis, Missouri, USA) on the microscope slide (Marienfeld-Superior, Lauda, Germany). The crude recombinant protein fragment (1 μl) of *PvRBP* was reacted to the amine-coated slide surface. After washing and blocking with PBS-T containing 5% bovine serum albumin (BSA), the array was probed with serial dilution (1:100 to 1:10) of malaria patient or healthy individual sera and with a 1:100 dilution of wheat germ lysate in PBS. Array conditions were optimized using 1:10 dilution of mixed sera from patients and healthy individuals. Alexa Fluor 546 goat anti-human IgG (Invitrogen) in PBS-T containing 1% BSA was applied into each spots for detection of the antibody reaction. The fluorescent signals were detected using a ScanArray Express fluorescence scanner (PerkinElmer, Boston, Massachusetts, USA). The cut-off value was defined as 3 standard deviations (SDs) above the mean fluorescence intensity (MFI) of the healthy individual samples. Recombinant *P. vivax* merozoite surface protein 1-19 (PvMSP1-19) was used as a positive control, and its MFIs were used for compensation in each slide.

Statistical analysis
--------------------

Data were analyzed using GraphPad Prism (GraphPad Software, San Diego, California, USA) and Excel 2013 (Microsoft, Redmond, Washington, USA). Statistical analysis of significance between *P. vivax* parasite-infected patients and healthy individual samples was performed with 2-tailed non-parametric Mann-Whitney U test. A *P*-value of \<0.05 was considered statistically significant.

RESULTS
=======

Bioinformatics analysis of *pvrbp* gene sequences
-------------------------------------------------

A total of 11 *pvrbps* genes including 3 homologue gene subfamilies of the PvRBP family (*pvrbp1s, pvrbp2s,* and *pvrbp3*) ([Table 1](#t1-kjp-53-4-403){ref-type="table"}) were selected for this study. The 3 pvrbp1 homologue genes in *P. vivax* Sal-1 included *pvrbp1a* (PVX_098585), *pvrbp1b* (PVX_098582), and pvrbp1-like partial sequence (PVX_125738) ([Fig. 1](#f1-kjp-53-4-403){ref-type="fig"}). *Pvrbp1a* and *pvrbp1b* encoded signal sequence at the N-terminal region in a full-length sequence. *Pvrbp1a* and *pvrbp1*-like partial sequence displayed a transmembrane domain near the C-terminus ([Table 2](#t2-kjp-53-4-403){ref-type="table"}). This *pvrbp1*-like partial sequence had 95% similarity with the C-terminal sequence of *pvrbp1b*, and was consistent with the typical RBL family structure.

The *pvrbp2* genes comprise 7 members that include *pvrbp2a* (PVX_121920), *pvrbp2b* (PVX_094255), *pvrbp2c* (PVX_121920), *pvrbp2d* (PVX_101585), *pvrbp2* like partial A (PVX_090330), *pvrbp2* like partial B (PVX_101590), and *pvrbp2* homologue B (PVX_116930) ([Fig. 1](#f1-kjp-53-4-403){ref-type="fig"}). *Pvrbp2d* was identified as a pseudogene. The other 6 *pvrbp2* homologue genes comprise 4 members with a full length sequence and 2 members with a partial sequence ([Table 1](#t1-kjp-53-4-403){ref-type="table"}). Among the *pvrbp2* genes, signal sequence and transmembrane domain were identified in *pvrbp2c*. Unlike other pvrbp genes, the *pvrbp2* homologue B gene consists of introns at both N-terminus and C-terminus, and displayed a shorter open reading frame (1,060 aa, 123.9 kDa) than those of other pvrbp sequences. Cysteine (Cys) residues and alpha helix coiled-coil region ectodomain structure were detected in *pvrbp2* homologue B. Accordingly, the *pvrbp2* homologue B was expected to evoke a higher immune response. *Pvrbp3* (PVX_101495) was observed as a pseudogene in the Sal-1 strain. All members of the pvrbps displayed large molecular weights exceeding 280 kDa and similar protein structure consisting of many Cys residues ([Table 1](#t1-kjp-53-4-403){ref-type="table"}; [Fig. 1](#f1-kjp-53-4-403){ref-type="fig"}).

Prediction of B-cell epitopes for PvRBPs
----------------------------------------

The prediction results of B-cell epitopes obtained by the 3 different B-cell prediction servers and protein fragment information are shown in [Table 2](#t2-kjp-53-4-403){ref-type="table"}. The prediction results of linear B-cell epitopes for PvRBP family displayed a wide range of fragments (3 to 29; median 13.9). According to the protein secondary structures and high probability of surface exposure, 20 fragments were selected as the potential specific B-cell epitopes for further study. The prediction results revealed that 5 fragments were located in the N-terminal region (PVX_098582-1, PVX_121920-1, PVX_090325-1, PVX_090330-1, and PVX_101590-1) and another 5 at the C-terminus (PVX_098585-2, PVX_125738-2, PVX_121920-4, PVX_094255-2, and PVX_090325-3). The specific domain feature contained alpha helix coiled-coil domain in 4 PvRBPs (PVX_098582-2, PVX_125738-1, PVX_090325-2, and PVX_090330-2) and repeat sequence with low complexity in 5 PvRBPs (PVX_098585-1, PVX_121920-2, PVX_121920-3, PVX_094255-1, and PVX_116930-2). PvRBP2-like homologue B fragment 1 (PVX_116930-1) did not represent any specific feature on protein secondary structure prediction. According to the B-cell epitope prediction, all of the fragments were likely to be surface-exposed and expected to be potently antigenic.

Expression of recombinant PvRBP protein fragments by cell-free expression system
--------------------------------------------------------------------------------

All the PvRBP recombinant proteins were expressed in the supernatant as the soluble fraction with variable expression level in the WGCF system. The expression level of the specific PvRBP proteins was confirmed by Western blot analysis with anti-His tag for detection of recombinant protein ([Fig. 2](#f2-kjp-53-4-403){ref-type="fig"}). Lower pI values of expressed PvRBP proteins were slower-migrating proteins on the SDS-PAGE analysis. The experimental positive control was PvMSP1-19, which was expressed by WGCF and purified by Ni-affinity chromatography as described previously \[[@b35-kjp-53-4-403]\]. These recombinant proteins were used for further analysis.

Humoral immune responses analysis of recombinant PvRBP proteins by protein microarray
-------------------------------------------------------------------------------------

The humoral immune responses of the PvRBP family fragment proteins were evaluated with sera from *P. vivax* patients and healthy individuals by protein microarray ([Table 3](#t3-kjp-53-4-403){ref-type="table"}). IgG prevalence to recombinant PVX_090325-1 and PVX_116930-2 fragments had the highest sensitivity (87.5%). Similarly, recombinant PvRBP2 fragments displayed high IgG positive responses; PVX_090330-1 (81.3%), PVX_094255-1 (75.0%), and PVX_116930-1 (75.0%) ([Table 3](#t3-kjp-53-4-403){ref-type="table"}). Recombinant PvRBP proteins from 6 fragments involving 2 fragments of PVX_125738 (coiled-coil and putative C-terminal domains), PVX_121920-1, -2, and -3 (N-terminal fragment, low complexity sequence, and repeat sequence, respectively), and PVX_090325-3 (C-terminal fragment) showed a similarly of 68.8% IgG-positive responses. Other fragments including PVX_098585-1 (repeat sequence), PVX_098582-2 (coiled-coli domain), and PVX_094255-2 (C-terminal domain) were 62.5% IgG-positive responses. The IgG prevalence below 60.0% was detected in PVX_090325-2 (containing a short coiled-coil domain), PVX_101590-1 (N-terminal region), PVX_098585-2 (C-terminal region), PVX_090330-2 (contained short coiled-coil domain), PVX_098582-1 (N-terminal region), and PVX_121920-4 (C-terminal region) ([Table 3](#t3-kjp-53-4-403){ref-type="table"}). The IgG prevalence of the overall PvRBP2s was higher than those of PvRBP1s. Recombinant PvRBP2 fragments displayed high positivity of IgG at the N-termini and repeat sequence regions. Most of recombinant PvRBP fragments showed high specificities and significantly different between *P. vivax* patients and healthy individuals (*P* \<0.05; [Table 3](#t3-kjp-53-4-403){ref-type="table"}).

DISCUSSION
==========

In the post-genomic era, the *P. vivax* complete genome sequences and bioinformatics information are available for various proteome-related approaches \[[@b14-kjp-53-4-403],[@b34-kjp-53-4-403],[@b36-kjp-53-4-403]-[@b38-kjp-53-4-403]\]. Bioinformatics tools for selection of proteins in *P. falciparum* have been used for new malaria antigenic protein identification. Antigenic proteins were considered from secondary structures, such as the alpha helical coiled-coil domain \[[@b36-kjp-53-4-403],[@b39-kjp-53-4-403]\]. In this study, humoral immune responses against recombinant PvRBP family proteins were evaluated by integration of bioinformatics with 3 prediction servers for B-cell epitopes, cell-free protein expression system, and protein microarray methods. The advantage of this strategy is easy selection of possible antigenic proteins and the ability to evaluate antigenicity in a small quantity of recombinant proteins.

A higher humoral immune response level was observed in PVX_116930-1 (391-510 aa) and PVX_116930-2 (635-769 aa) than those of the other PvRBP family genes (75.0% and 87.5%, respectively) ([Table 3](#t3-kjp-53-4-403){ref-type="table"}). Especially, PVX_116930-2 contained the sequence (~663~KSPEPL~692~) that was repeated 5 times, possibly to elicit high antigenicity. Although this protein expression level was not specific in schizont stage, overall it was highly conserved regardless of the strain \[[@b40-kjp-53-4-403]\]. BLAST analysis revealed a close relationship with *P. falciparum* conserved protein (PF3D7_0305200) and PvRBP2 homologue B (PVX_116930) with a 41% sequence similarity in alpha helical coiled-coil domains. Although the exact function of the PF3D7_0305200 has not yet been defined, it has the expected high antigenicity \[[@b13-kjp-53-4-403],[@b41-kjp-53-4-403]-[@b43-kjp-53-4-403]\]. This evidence supports the potential of PvRBP2 homologue B (PVX_116930) as an antigenic serological marker. The alpha helical coiled-coil domain has demonstrated high antigenicity in a broad variety of antigens of parasites that include *Plasmodium* spp. \[[@b38-kjp-53-4-403],[@b39-kjp-53-4-403],[@b43-kjp-53-4-403]\]. The recombinant proteins as coiled-coil domain elicit the antigenicity, consistent with previous studies \[[@b36-kjp-53-4-403],[@b38-kjp-53-4-403],[@b39-kjp-53-4-403],[@b44-kjp-53-4-403]\]. PvRBP2 homologue B may an important antigenic protein of the PvRBP family and could be useful serological markers for *P. vivax*.

Although the similarity of PvRBP family gene sequence was low, these homologue genes presented a typical RBL family structure, which consisted of a large exon (ectodomain) and small cytoplasmic tails, such as type 1 transmembrane proteins. The PvRBP family has an expected specific function involved in reticulocyte recognition during host cell invasion \[[@b19-kjp-53-4-403]\]. The typical RBL family proteins, PvRBP1a and PvRBP2c, bind to reticulocytes \[[@b19-kjp-53-4-403],[@b20-kjp-53-4-403]\]. Transcription results of the PvRBP family indicate that RBP1a is highly expressed during blood stage parasites. Presently, a new antigenic RBP protein, PvRBP2 homologue B, was confirmed to be consistently expressed during blood stage parasite development. Localization, expression level and pattern, and reticulocyte binding ability of this protein need to be explored.

The sequence diversity analysis of PvRBP1 revealed that the N-terminal region of the protein contains polymorphic residues with non-synonymous polymorphisms relating with immune selection pressure \[[@b44-kjp-53-4-403],[@b45-kjp-53-4-403]\]. In contrast, PvRBP2 homologue B is highly conserved in worldwide isolate; however, coiled-coil domain has immune selection. In this study, antigenicity of most of the PvRBP2 family including the PvRBP2 homologue B was higher than that of the PvRBP1 family. This result may reflect the high genetic diversity in PvRBP2 compared to PvRBP1 \[[@b46-kjp-53-4-403]\]. Moreover, high prevalence of total IgG represents the repeat sequence and both termini of PvRBP2 family. Especially N-terminal part of PvRBP2c (PVX_090325-1) and PvRBP2 partial A (PVX_090330-1) represent high antigenicity (87.5% and 81.3%, respectively) with sequence similarity (60%). These domains may also play an important role for recognition of antibodies.

In summary, this study is the first evaluation of the humoral immune responses against fragments of PvRBP family proteins with predicted B-cell epitope regions in vivax malaria patients and healthy individuals. A high prevalence of total IgG against the fragment of PvRBP2 homologue B (PVX_116930) was detected, implicating the fragment as a potential serological marker. A high prevalence of total IgG in PvRBP2 family genes was observed in the alpha helical coiled-coil motif and at the N-terminus. The present findings will be valuable for serological marker candidates.
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![Schematic protein features and secondary structures of the PvRBP family. The PvRBP family based on amino acid (aa) length. Black bar denotes fragment for recombinant protein expression, with the order of fragment number from the N-terminal region. RDG, arginyl-glycyl-aspartic acid a cell adhesion motif.](kjp-53-4-403f1){#f1-kjp-53-4-403}

![Recombinant protein expressions of PvRBP family fragments by Western blot analysis. All the PvRBP recombinant proteins were expressed in the supernatant as the soluble fraction with variable expression level in the wheat germ cell-free expression system. The expression level of each PvRBP protein was detected by Western blot analysis probed with anti-His tag. kDa, kilodalton; T, total crude protein; S, supernatant soluble fraction.](kjp-53-4-403f2){#f2-kjp-53-4-403}

###### 

General information of *Plasmodium vivax* reticulocyte binding like protein (PvRBP)

  Name                      Gene ID (PVX\_)   Chromosome No.   Length (aa)   MW (kDa)   SP   TM   Expression stage   Note             Reference
  ------------------------- ----------------- ---------------- ------------- ---------- ---- ---- ------------------ ---------------- ---------------------------------------------
  PvRBP1a                   098585            7                2,833         326.2      Y    Y    Schizont           Full length      \[[@b19-kjp-53-4-403],[@b23-kjp-53-4-403]\]
  PvRBP1b                   098582            7                2,608         303.3      Y    N    Unknown            Full length      \[[@b14-kjp-53-4-403]\]
  PvRBP1 like-partial       125738            NA               785           90.9       N    Y    Unknown            Partial length   \[[@b14-kjp-53-4-403]\]
  PvRBP2a                   121920            14               2,487         286.6      Y    N    Schizont           Full length      \[[@b14-kjp-53-4-403],[@b21-kjp-53-4-403]\]
  PvRBP2b                   094255            8                2,806         325.5      Y    N    Schizont           Full length      \[[@b14-kjp-53-4-403],[@b21-kjp-53-4-403]\]
  PvRBP2c                   090325            5                2,824         326.4      Y    Y    Schizont           Full length      \[[@b19-kjp-53-4-403],[@b23-kjp-53-4-403]\]
  PvRBP2 like-partial A     090330            5                623           72.8       Y    N    Schizont           Partial length   \[[@b14-kjp-53-4-403],[@b21-kjp-53-4-403]\]
  PvRBP2 like-partial B     101590            14               640           74.2       Y    N    Unknown            Partial length   \[[@b14-kjp-53-4-403],[@b21-kjp-53-4-403]\]
  PvRBP2 like-homologue B   116930            12               1,060         123.9      Y    N    Unknown            Full length      \[[@b14-kjp-53-4-403],[@b21-kjp-53-4-403]\]
  PvRBP2d                   101585            14               2,829         329.1      Y    Y    Null               Pseudogene       \[[@b21-kjp-53-4-403]\]
  PvRBP3                    101495            14               2,798         323.1      N    Y    Null               Pseudogene       \[[@b21-kjp-53-4-403]\]

aa, amino acid; MW, molecular weight; kDa, kilodalton; SP, signal peptide; TM, transmembrane domain; NA, not assigned.

###### 

Primer sequences for recombinant PvRBP family protein expressions

  Fragment (PVX\_)   Forward primer (5ʹ→3ʹ)           Reverse primer (5ʹ→3ʹ)        Position (aa)   Length (aa)   pI    MW (kDa)
  ------------------ -------------------------------- ----------------------------- --------------- ------------- ----- ----------
  098585-1           CAAAACAGCATGCAGCAGTAC            TTCGTCTACTTCCCTTTTGATGT       804-1,073       270           5.1   34.4
  098585-2           GAAATGAATTCTAAAAAGAGCGCT         TTCTTCTTTGTTTTCTGGGTTCA       2,619-2,822     204           4.2   25.6
  098582-1           GTAGATTTAAATCGAGGGAAAAACAC       GCAGCTGGATTGCTTCAAA           15-289          273           6.7   34.7
  098582-2           GATAAGTTGAAAGCAGAACTAGGAAGT      GATCTGTTGTGTTTGCTCTTCC        996-1,254       259           5.6   33.8
  125738-1           CTAGAAAATGACAAAAGGAAAAAGAGC      AATGTCTGTTTGAGGGGGTAGTC       476-623         148           4.6   20.0
  125738-2           AAAAATGACAGAAACGATCAAAAAT        ATCTTTTACATTACGTTTTGAACCATT   630-772         143           5.4   18.9
  121920-1           TCAAGCAAAGAAAGCAATCG             TATTTGATTCTTTGGTGTGAAGAGAA    20-145          126           9.7   17.7
  121920-2           AGCGAAAAAATAGATAAAAATTTGGA       CATATCGTCGACTAATTCTTTTAAGTC   453-713         261           5.2   33.3
  121920-3           ACGGAAGCTAAAACACTCAGG            TGTGTCGTAATTCTTATCATCCGT      1,789-2,049     261           5.8   32.9
  121920-4           GCTAAGGAAAACTCCATTAATATGC        TTCTTCCTTATCTTGAAGATTTCCA     2,330-2,474     145           7.4   19.0
  094255-1           CAAGAAGCTTCCTACCAAAATGC          TGCAATATTCACTTTCTTAATGGAGT    728-965         238           4.7   30.7
  094255-2           GATACCCAAGAGAACGATACAGAC         TTCAGAATAATCGCTATTGTCGAA      2,673-2,806     134           4     18.2
  090325-1           AGGAATGGTCAACACAAATACAAC         TACAATTTCAGGGGCCTCTG          47-171          125           9.7   18.0
  090325-2           CTAAAAGCAAGCTCGAACGATC           GTATTTATCAGCATTTGATTTCATTTC   2,115-2,314     200           5     25.7
  090325-3           GCAAAAGTTGAGCCTGAAGC             ATCTTCTTCATTAAAGCAAACTTCG     2,652-2,824     173           3.9   22.3
  090330-1           AGGGATGATCAAAACGGACA             TGAATTTGGAACACTATGCAATTC      47-145          99            8.4   14.4
  090330-2           GAAAATCCAGAACACTATAAAAATAAGAGA   AATTTCATCTATTACGAAATCTGCC     242-370         129           6.8   18.5
  101590-1           AAGGATGTCAATCGAAACAAACC          ATGCAATTTTTTATTATCATCTTCCAT   22-145          124           7.5   17.2
  116930-1           TTGCACAATTCGACCTCC               AACCATGCTGCCTTCGTAC           359-477         119           6.3   16.6
  116930-2           GATAACATCAAGAGGAGGAACGC          CAGTTTGAAATTTTTATCGATGTTGT    603-736         134           9.7   19.4

pI, isoelectric point.

###### 

Total IgG prevalence of each recombinant PvRBP protein including predicted B-cell epitope domain

  Antigen (PVX\_)   No. of patients samples (*n*)   95% Ci^[b](#tfn2-kjp-53-4-403){ref-type="table-fn"}^ (%)   MFI^[c](#tfn3-kjp-53-4-403){ref-type="table-fn"}^   No. of healthy samples (*n*)   95% CI (%)   MFI   *P*-value^[e](#tfn5-kjp-53-4-403){ref-type="table-fn"}^   Features/Structures                                 
  ----------------- ------------------------------- ---------------------------------------------------------- --------------------------------------------------- ------------------------------ ------------ ----- --------------------------------------------------------- --------------------- ------------ ------- -------- -------------------
  098585-1          10                              6                                                          16 (62.5)                                           38.6-81.5                      6,429        0     8                                                         8 (100.0)             67.6-100.0   3,139   0.0013   Repeat sequence
  098585-2          8                               8                                                          16 (50.0)                                           28.0-72.0                      5,480        0     8                                                         8 (100.0)             67.6-100.0   2,943   0.0016   C-terminal
  098582-1          6                               10                                                         16 (37.5)                                           18.5-61.4                      5,806        0     8                                                         8 (100.0)             67.6-100.0   3,275   0.0011   N-terminal
  098582-2          10                              6                                                          16 (62.5)                                           38.6-81.5                      6,566        0     8                                                         8 (100.0)             67.6-100.0   3,181   0.0004   Coiled coil
  125738-1          11                              5                                                          16 (68.8)                                           44.4-85.8                      9,242        0     8                                                         8 (100.0)             67.6-100.0   3,970   0.0002   Coiled coil
  125738-2          11                              5                                                          16 (68.8)                                           44.4-85.8                      10,280       0     8                                                         8 (100.0)             67.6-100.0   3,741   0.0003   C-terminal
  121920-1          11                              5                                                          16 (68.8)                                           44.4-85.8                      11,283       0     8                                                         8 (100.0)             67.6-100.0   4,628   0.0013   N-terminal
  121920-2          11                              5                                                          16 (68.8)                                           44.4-85.8                      9,232        0     8                                                         8 (100.0)             67.6-100.0   3,863   0.0007   Low complexity
  121920-3          11                              5                                                          16 (68.8)                                           44.4-85.8                      8,821        0     8                                                         8 (100.0)             67.6-100.0   3,010   0.0005   Repeat sequence
  121920-4          6                               10                                                         16 (37.5)                                           18.5-61.4                      6,947        0     8                                                         8 (100.0)             67.6-100.0   3,710   0.0053   C-terminal
  094255-1          12                              4                                                          16 (75.0)                                           50.5-89.8                      13,325       0     8                                                         8 (100.0)             67.6-100.0   5,163   0.0007   Repeat sequence
  094255-2          8                               8                                                          16 (62.5)                                           28.0-72.0                      6,307        0     8                                                         8 (100.0)             67.6-100.0   3,394   0.0011   C-terminal
  090325-1          14                              2                                                          16 (87.5)                                           64.0-96.5                      17,597       0     8                                                         8 (100.0)             67.6-100.0   6,257   0.0002   N-terminal
  090325-2          9                               7                                                          16 (56.3)                                           33.2-76.9                      19,179       0     8                                                         8 (100.0)             67.6-100.0   7,226   0.0004   Short coiled coil
  090325-3          11                              5                                                          16 (68.8)                                           44.4-85.8                      18,615       0     8                                                         8 (100.0)             67.6-100.0   6,095   0.0007   C-terminal
  090330-1          13                              3                                                          16 (81.3)                                           57.0-93.0                      12,413       0     8                                                         8 (100.0)             67.6-100.0   4,455   0.0002   N-terminal
  090330-2          7                               9                                                          16 (43.8)                                           23.1-66.8                      12,149       0     8                                                         8 (100.0)             67.6-100.0   6,072   0.0030   Short coiled coil
  101590-1          9                               7                                                          16 (56.3)                                           33.1-76.9                      7,223        0     8                                                         8 (100.0)             67.6-100.0   3,299   0.0005   N-terminal
  116930-1          12                              4                                                          16 (75.0)                                           50.5-89.8                      12,407       0     8                                                         8 (100.0)             67.6-100.0   4,522   0.0004   Short coiled coil
  116930-2          14                              2                                                          16 (87.5)                                           64.0-96.5                      11,332       0     8                                                         8 (100.0)             67.6-100.0   3,346   0.0005   Repeat sequence
  PvMSP1-19         4                               0                                                          4 (100.0)                                           51.0-100.0                     9,987        0     8                                                         8 (100.0)             67.6-100.0   1,887   0.0286   

Sensitivity, percentage of positives in patient samples.

CI, confidence intervals.

MFI, mean fluorescence intensity.

Specificity, percentage of negatives in healthy samples.

Differences in the total IgG prevalence for each antigen between patients and healthy individuals were calculated with Mann-Whitney U test. *P*\<0.05 considered as statistically significant.
